Monotherapy with bedaquiline, a diarylquinoline used to treat pulmonary multidrug-resistant tuberculosis, is efficacious in patients with multibacillary leprosy, suggests a phase 2, open-label study in Brazil. Nine adult patients with previously untreated leprosy consisting of at least six skin lesions received oral bedaquiline 200 mg once daily for 2 weeks, followed by bedaquiline 100 mg three times per week for 6 weeks. After 8 weeks of bedaquiline, patients started standard multidrug therapy for leprosy.